Replies to post #34113 on Intellipharmaceutics International Inc. (IPCI)

[Biotech junkie]

I wouldn't put any money on Odidi at this point.
My guess is q1 will show stagnant earnings and big cash depletion. We will be back to square one, back out of nas compliance and another offering on the way. Hope they prove me wrong, but highly unlikely as history shows.

[doogdilinger]

So if we do get a bit of a cover coinciding with Q1 earnings and hopefully news on launching the long expected CAT 2 & 3 Studies in Humans on their Oxy NDA Candidate...along with news on their PODRAS POC Trials in humans initiating...that tri-fecta of materials announcements would/should certainly be enough to propel the share price high enough to start testing the 200DMA!